Aparna Kalyan, MD


Future Treatment Approaches for HCC

Closing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.

Mark A. Davis, MD, MS


Baptist Health Adopts Innovative AI Solutions, Cutting-Edge Research to Address Complexities of Care

The rapid progress in oncology, along with complex cases and rising costs, presents challenges in delivering high-quality cancer care.

Rose McNulty


Boland Discusses Melanoma Treatment Updates

Genevieve Boland, MD, PhD, discusses the latest updates to the melanoma treatment landscape.

Susan Bal, MD


Bal on Targeting GPRC5D in R/R Multiple Myeloma

Susan Bal, MD, discusses novel targets for relapsed/refractory multiple myeloma at the 2023 Annual Meeting.

Julie Chang, MD


Novel Approaches in MCL Treatment and Predictive Insights

Julie Chang, MD, discusses the reasoning behind the development of a minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma.

Amanda Blackmon, DO


Improving Access to Bone Marrow Transplant and Cellular Therapies

Stem cell treatments offer hope for a variety of conditions. However, access to these potentially life-altering procedures is often hampered by social factors such as socioeconomic status, race, cultural background, and geographic location.

Miranda Lankas


Ra-223 Demonstrates Safety, Efficacy in Managing Bone Metastases in Prostate Cancer

Patients diagnosed with bone metastatic, castration-resistant prostate cancer and treated with radium-223 showed lower incidences of treatment-related adverse events or treatment discontinuation, particularly when used in the front-line setting.

Leslie Busby, MD


MTD Practices Spotlight Shortcomings of Value-Based Care

Leslie T. Busby, MD, discusses the shift from dose-dependent chemotherapy to the challenge of managing toxicities in biologic and targeted therapies, which are often erroneously developed using the maximum tolerated dose paradigm.

Christina L. Roland, MD, PhD


Neoadjuvant Blockade Demonstrates Significant Clinical Activity in UPS

Christina L. Roland, MD, PhD, discusses the preliminary results of neoadjuvant checkpoint blockade—nivolumab or nivolumab plus ipilimumab—in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Sagun Shrestha, MD


Screening for SCLC Can Change Overall Prognosis

The push for more screening of patients with a history of smoking is providing oncologists the ability to catch small cell lung cancers earlier and potentially change the prognosis of the disease.

George Nahas, DO


Growing Use of Bispecifics for the Treatment of Multiple Myeloma

George Nahas, DO, discusses ongoing research that may shape the future treatment landscape of multiple myeloma.

Jeffrey R. Schriber, MD, FRCP


Examining Changes in the Multiple Myeloma Treatment Landscape

Jeffrey R. Schriber, MD, FRCP, discusses some of the available treatment options for patients with multiple myeloma and how the treatment landscape has evolved over time.

Morgan Bayer


Ciltacabtagene Autoleucel Produces Deep, Durable Responses in Multiple Myeloma

In early lines of therapy for relapsed/refractory multiple myeloma, patients receiving cilta-cel demonstrated deep and enduring responses, with overall response rates of 95% and 100% in 2 cohorts.

Guillermo Garcia-Manero, MD


New Horizons in the Management of MDS

Future perspective on the growing treatment landscape for patients with MDS.

Sonya Collins


10 Years in CLL: Top Advances From 2012-2022

The past decade has seen the FDA approve a handful of new targeted therapies for chronic lymphocytic leukemia that are prompting a move toward chemotherapy-free treatment of the disease.

Colleen Danielson, NP, Massachusetts General Hospital


Future Directions in Graft Versus Host Disease

Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.

Javier Cortes, MD, PhD


Pembrolizumab Plus Chemotherapy Show Efficacy for TNBC in KEYNOTE-355

Javier Cortes, MD, PhD, discusses the data from the phase 3 KEYNOTE-355 trial of pembrolizumab and chemotherapy versus placebo and chemotherapy for previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer.

Sara Rogers, PharmD


Differentiating Pseudoprogression From Hyperprogression in Patients Treated With Immunotherapies

Advances in the field have also led to the recognition of other clinical challenges, including unforeseen observations and complications associated with choosing the sequencing of appropriate therapeutic interventions as well as the management of drug-related complications.

Ryan McDonald


Ibrutinib Plus Venetoclax May Be an Effective Treatment for Previously Untreated WM

Fast and durable response were seen in patients with Waldenström Macroglobulinemia who received the combination of ibrutinib and venetoclax.

Ming Zhao, MD


Discussing the FOHAIC-1 Study for Patients With HCC

Ming Zhao, MD, explains the background of the FOHAIC-1 study.

Bridget Koontz, MD


Breast Cancer Awareness Month: What to Know for Different Types of Breast Cancer

For Breast Cancer Awareness Month Kristina Mirabeau-Beale, mD, MPH, and Bridget Koontz, MD, discuss the different types of breast cancer that clinicians need to be aware of.

Heather McArthur, MD


Case 3: Role of Preoperative Endocrine Therapy in HR+ High-Risk Breast Cancer

Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.

Tina Cascone, MD, PhD


CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC

Tina Cascone, MD, PhD, discusses the main findings from the phase 3 CheckMate-77T trial of a nivolumab-based regimen for the treatment of patients with stage IIA to IIIB non–small cell lung cancer.

Eileen Gamagami, PhD


Long-Term Management of Patients with P53 Aberrations

Treatment approaches to address mutations or deletions of chromosome 17p are needed due to the surfacing of point mutations, including TP53 aberrations in chronic lymphocytic leukemia.

Andrew A. Lane, MD, PhD


Multi-Stage Trial of Tagraxofusp Shows Frontline Efficacy in BPDCN

Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.